<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: Alterations in the <z:mp ids='MP_0011356'>RAS</z:mp>-RAF-MAP2K (MEK)-MAPK signaling pathway are major drivers in colorectal <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>In <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, BRAF mutation is associated with microsatellite instability (MSI), and typically predicts inferior prognosis </plain></SENT>
<SENT sid="2" pm="."><plain>We examined the effect of BRAF mutation on survival and treatment efficacy in patients with stage III <z:hpo ids='HP_0003003'>colon cancer</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Methods: We assessed status of BRAF c.1799T&gt;A (p.V600E) mutation and MSI in 506 stage III <z:hpo ids='HP_0003003'>colon cancer</z:hpo> patients enrolled in a randomized adjuvant chemotherapy trial [<z:chebi fb="0" ids="46345">5-fluorouracil</z:chebi> and leucovorin (FU/LV) vs. irinotecan (CPT11), FU and LV (IFL); CALGB 89803] </plain></SENT>
<SENT sid="4" pm="."><plain>Cox proportional hazards model was used to assess the prognostic role of BRAF mutation, adjusting for clinical features, adjuvant chemotherapy arm, and MSI status </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Compared with 431 BRAF <z:mp ids='MP_0002169'>wild-type</z:mp> patients, 75 BRAF-mutated patients experienced significantly worse overall survival [OS; log-rank P = 0.015; multivariate HR = 1.66; 95% CI: 1.05-2.63] </plain></SENT>
<SENT sid="6" pm="."><plain>By assessing combined status of BRAF and MSI, it seemed that BRAF-mutated <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSS</z:e> (microsatellite stable) <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> was an unfavorable subtype, whereas BRAF <z:mp ids='MP_0002169'>wild-type</z:mp> MSI-high <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> was a favorable subtype, and BRAF-mutated MSI-high <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> and BRAF <z:mp ids='MP_0002169'>wild-type</z:mp> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSS</z:e> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> were intermediate subtypes </plain></SENT>
<SENT sid="7" pm="."><plain>Among patients with BRAF-mutated <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, a nonsignificant trend toward improved OS was observed for IFL versus FU/LV arm (multivariate HR = 0.52; 95% CI: 0.25-1.10) </plain></SENT>
<SENT sid="8" pm="."><plain>Among patients with BRAF <z:mp ids='MP_0002169'>wild-type</z:mp> <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>, IFL conferred no suggestion of benefit beyond FU/LV alone (multivariate HR = 1.02; 95% CI: 0.72-1.46) </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: BRAF mutation is associated with inferior survival in stage III <z:hpo ids='HP_0003003'>colon cancer</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>Additional studies are necessary to assess whether there is any predictive role of BRAF mutation for irinotecan-based therapy </plain></SENT>
</text></document>